News FDA panel backs Ardelyx CKD drug, despite agency concerns While the FDA seems to remain sceptical about the clinical benefits of Ardelyx's chronic kidney disease (CKD) therapy Xphozah – having
News Hard times at Ardelyx as FDA rejects kidney disease drug ten... The FDA has taken a longer than usual look at Ardelyx's regulatory submission for tenapanor, a drug for high blood phosphate levels associated with chronic kidney disease (CKD), and found i
Views & Analysis Ardelyx’s ambition to revolutionise kidney treatment A therapy to treat hyperphosphatemia is moving closer to the market after years of development by California-based company Ardelyx.
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face